Figure 5.

Compound 38 treatment reduces liver inflammation and fibrosis.

Mice received intraperitoneal injections of CCl₄ (10% CCl₄ dissolved in olive oil at a dose of 1 mL/kg body weight) twice a week. (a) Serum ALT and AST levels in mice from the normal control (NC; n = 11), CCl₄-induced liver fibrosis model (n = 9), and model with compound 38 treatment (n = 9) groups. (b) Representative images of Masson staining from the mouse liver tissues of the indicated groups. (c and d) Representative images of immunohistochemical staining for COL1α1 (c) and α-SMA (d) in liver sections. (e) Quantification of different stainings (n = 10 images per group from the NC, CCl₄, and CCl₄ + compound 38 groups; six samples per group). Data represent the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to CCl₄-induced mice. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 compared to the control group.